The Partnership for Safe Medicines has been publishing information about the counterfeit drug problem around the world for more than a decade. With experts leading the organization and a committed and passionate set of writers and editors, our content is more in-depth than many other sources, which simply copy links to the news from other websites.
“What we don’t need in this situation are companies preying on consumers by promoting products with fraudulent prevention and treatment claims. These warning letters are just the first step. We’re prepared to take enforcement actions against companies that continue to market this type of scam.”
Each year, the U.S. Drug Enforcement Administration pools the knowledge of law enforcement agencies around the country to produce its National Drug Threat Assessment. This year, fentanyl, counterfeit prescription pills, and the pill presses are all listed as things that will continue to endanger American lives…
Yesterday ended a 78-day comment period for the White House’s proposal to import medicine from Canada. In all, over 1,000 comments were filed. Overwhelmingly, these comments opposed the proposed rule or expressed skepticism that the rule could meet the two requirements listed in the Medicare Modernization Act of 2003: be safe and save consumers money. In fact, when you read the comments, it is clear that this policy is overwhelming opposed by experts on the issues of economics and medicine safety.
According to a notice on the L.A. City Attorney’s website, the Dominguez family allegedly ran a counterfeit drug operation that sold approximately 13,848 counterfeit and misbranded pharmaceuticals, including counterfeit and misbranded versions of anti-seizure and blood pressure medications, injectable birth control and steroids, among others.
This editorial by Peter J. Pitts was published in The Times Weekly on March 3, 2020. Mr. Pitts is president of the Center for Medicine in the Public Interest and a former FDA associate commissioner. Keep Canadian drugs out of U.S. medicine cabinets The Trump administration recently proposed two rules that would allow states, pharmacies,…
WHOIS data is searchable registrar information available for all websites on the Internet. It has long been used to trace criminal websites that host counterfeit and illicit drug sales, human trafficking, child pornography, and illicit and copyrighted content, as well as the websites of spammers, denial-of-services and phishing attackers, and other fraudsters.
In this editorial in The Globe and Mail, Ujjal Dosanjh, formerly a federal minister of health and a premier of British Columbia, explains that drug manufacturers have no incentive to sell Canadian provinces more medicine to fill the needs of U.S. residents. Importation will lead to drug shortages in Canada and counterfeit drug trafficking to the U.S.
This is a reprint of an FDA Alert. When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company’s announcement as a public service. FDA does not endorse either the product or the company. Company Announcement Date: February 24, 2020 FDA Publish Date: February 24, 2020 Product Type: Dietary Supplements…
The U.S. Food and Drug Administration (FDA) has just announced a successful joint operation with the Government of India targeting counterfeit prescription drugs, counterfeit over-the-counter medications, fake medical devices, and misbranded dietary supplements containing harmful ingredients.
Today The Partnership for Safe Medicines filed comments with Health and Human Services about the dangers posed by its draft regulations for state-based Canadian drug importation programs. PSM cited historic problems with and patient harm from Canadian vendors selling counterfeit medications to U.S. patients and medical practices; showed broad opposition to the plan by Canadian stakeholders; and provides alternatives that don’t impact patient safety.